Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study-Reference-Cited by-同舟云学术

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Published:2022-01 Issue:1 Volume:10 Page:47-58
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Menzies-Gow Andrew,Gurnell Mark,Heaney Liam G,Corren Jonathan,Bel Elisabeth H,Maspero Jorge,Harrison Timothy,Jackson David J,Price David,Lugogo Njira,Kreindler James,Burden Annie,de Giorgio-Miller Alex,Padilla Kelly,Martin Ubaldo J,Garcia Gil Esther

Funder

AstraZeneca PLC

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference30 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

2. Future risks in patients with severe asthma;Song;Allergy Asthma Immunol Res,2019

3. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature;Volmer;Eur Respir J,2018

4. Systematic literature review of systemic corticosteroid use for asthma management;Bleecker;Am J Respir Crit Care Med,2020

5. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma;Voorham;Allergy,2019

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab;The Journal of Allergy and Clinical Immunology: In Practice;2024-08

2. Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia;Respiratory Medicine;2024-08

3. Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab;Clinical & Experimental Allergy;2024-07-31

4. Type 2 severe asthma: pathophysiology and treatment with biologics;Expert Review of Respiratory Medicine;2024-07-02

5. Expert consensus on oral corticosteroids stewardship for the treatment of severe asthma in the Middle East and Africa;Respiratory Medicine;2024-07